Ethan Bubba

Public health and prevention programs including the Public Health Agency of Canada and efforts to support the development and procurement of innovative vaccines and therapies to address major public health issues such as pandemic preparedness and RSV Federally-funded public drug plans, including the Non-Insured Health Benefits program, Canadian Armed Forces Drug Benefit List and veteran programs, with respect to reimbursement for drug products for beneficiaries Canada's Drug Agency policies and processes as it relates to reimbursement recommendation decision-making process and framework Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry Establish accountability with Health Canada, Canada’s Drug Agency and the pan-Canadian Pharmaceutical Alliance, as well as Regulations, policies and programs related to the review and reimbursement processes Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB) Engagement with the Government regarding the Strategic Response Fund (SRF) (previously known as SIF) and investment in Canada Annual federal Budgets and Budget updates relating to the biopharmaceutical industry. Scientific Research and Experimental Development (SR&ED) Tax Incentive Program regarding eligible expenditures. Discussions on policies such as "patent box" and Investment Tax Credits.

Protect children and youth from online harms by advancing evidence-informed policies (Bill C-34) that promote safer digital environments, support healthy development and well-being, and strengthen protections against harmful online content, interactions, and platform practices. PT stream of the Build Communities Strong Fund, specifically the $5 billion announced specifically for healthcare infrastructure, making sure that children's healthcare needs are taken into account in the program development. Creation of an Indigenous Guiding Circle within Children's Healthcare Canada to provide guidance and counsel on how to better advocate for FNIM children and youth health issues. Protect the Public Health Agency of Canada’s critical work, building confidence in vaccines for children and combatting mis and disinformation influencing decisions impacting children’s health. Protect and expand capacity to deliver on Jordan’s Principle and the Inuit Child First Initiative (a federal responsibility); Top up and broaden the eligibility for the Youth Mental Health Fund, with a focus on prevention, early assessment and rapid intervention in the early years; Include Children’s Priorities in Nation-Building Investments : Asking for capital investments in the children’s healthcare system, including support for research, workforce planning, and the implementation of learning health systems. Advancing a National Children's Strategy to advance child and youth health and well-being outcomes.